Basel, Switzerland, November 1 (ots/PRNewswire) - A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.(1) Comparing Today's Standard Treatment Regimens: The Milan Safety Tolerability ...
Basel, Switzerland (ots/PRNewswire) - - MabThera Shown to be Effective and Well Tolerated Over the Long-Term A study(1) has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in their condition with each subsequent treatment course. The patients in ...
Basel, Switzerland (ots/PRNewswire) - Avastin (bevacizumab) remains the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC). Avastin's strong position was confirmed ...
Basel, Switzerland (ots/PRNewswire) - - Final Analysis of Study Confirms Benefit of Avastin(R) for Patients With Lung Cancer BASEL, Switzerland, September 15 /PRNewswire/ -- The final analysis of the Avastin in lung study (AVAiL) in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it ...
Stockholm (ots/PRNewswire) - - Patients Live Longer After Treatment With Capecitabine Chemotherapy Combinations Compared With Standard IV 5-FU/FA - For Non-US and Non-UK Media Only Pooled results of two phase III trials have shown that stomach and oesophageal cancer patients treated with oral chemotherapy Xeloda (capecitabine) lived approximately one ...
Basel, Switzerland (ots/PRNewswire) - - Avastin Shows Unprecedented Patient Benefits Regardless of K-Ras Status, Age and Chemotherapy Choice Avastin's (bevacizumab) essential role in the treatment of patients with metastatic colorectal cancer (mCRC), the world's second most common cancer, was ...
Basel, Switzerland (ots/PRNewswire) - - 100+ Abstracts on Roche Medicines Feature at This Congress More than 100 Roche abstracts have been accepted for the biggest cancer congress in Europe, the European Society for Medical Oncology (ESMO), which opens in Stockholm on Friday (12th September). The Roche abstracts include the latest data on Avastin ...
Basel, Switzerland (ots/PRNewswire) - - Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera (rituximab) as ...
Basel, Switzerland (ots/PRNewswire) - The European Committee for Human Medicinal Products (CHMP) has confirmed that the presence of an impurity called ethyl methanesulfonate (EMS) in Roche's Viracept (nelfinavir mesylate) did not increase patients' risk of developing cancer. The discovery of the EMS impurity ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only - Avastin is the Only Biologic Proven to Extend Life in Patients With Normal K-Ras Gene Data presented today at the 10th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona confirm that Avastin (bevacizumab) significantly improves ...
Barcelona, Spain (ots/PRNewswire) - - Analysis Confirms That Oral Xeloda is Superior to IV 5-FU - Not for US Media A pre-planned multivariate analysis of the five-year follow-up data shows that patients receiving chemotherapy after-surgery to treat colon cancer, are more likely to live longer when taking the chemotherapy pill Xeloda (capecitabine), compared to those receiving 5-FU/FA intravenous (IV) ...
Basel, Switzerland (ots/PRNewswire) - - Roche Also Announces Start of NCORE Study to Determine Best Length of Treatment in Patients who do not Experience a Rapid Response Roche announced today that the European Commission has approved a shortened, 16-week course of treatment with Pegasys ...
Barcelona (ots/PRNewswire) - - Not for US Media - Comparative Analysis Shows Chemotherapy Pill Xeloda Should Become Standard of Care in Colon, Colorectal and Stomach Cancers Results from a meta-analysis involving data from six phase III studies show that patients taking the chemotherapy pill Xeloda actually live longer than those receiving intravenous ...
London (ots/PRNewswire) - - Few Countries Have Prioritised This Potentially Preventable and Curable Cancer The first cross-country report on the management and funding of colorectal cancer (CRC) reveals an urgent need for action to improve the survival of patients diagnosed with this common cancer in ...
Basel, Switzerland (ots/PRNewswire) - - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating ...
Basel, Switzerland (ots/PRNewswire) - - New Data Also Proves MabThera's Inhibition of Joint Damage is Maintained Over Two Years A recent study(1) has called into question the practice of putting rheumatoid arthritis (RA) patients onto a second tumour necrosis factor (TNF) inhibitor therapy, a commonly ...
Basel, Switzerland (ots/PRNewswire) - - Data From Pivotal Phase III AVADO Study Presented at ASCO for the First Time Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease getting worse ("progression-free survival") when combined with a ...
Basel, Switzerland (ots/PRNewswire) - - Results Confirm Previously Demonstrated Survival Advantages of Tarceva in This Difficult-to-Treat Disease - ABSTRACT No: 4507 Adding Avastin (bevacizumab) to a combination of Tarceva (erlotinib) and chemotherapy significantly improves the time patients with metastatic pancreatic cancer live without their disease ...
Basel, Switzerland (ots/PRNewswire) - - Thousands Of Patients Benefit Provided From Avastin-Based Therapy A wealth of new Avastin (bevacizumab) data will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirming that Avastin-based therapy is essential for patients with metastatic colorectal cancer ...
Stockholm (ots/PRNewswire) - - Report Benchmarks the Current State of Lung Cancer Care Across Europe The fragmented organization and management of lung cancer diagnosis and care in many European countries are exacerbating already poor survival rates amongst patients with the disease. That is the conclusion of a new report from a group of leading ...
Chicago, Illinois (ots/PRNewswire) - - Tarceva Extends Length and Quality of Life in Largest Non-Small Cell Lung Cancer (NSCLC) Phase IV Study Ever Conducted - For non-US and non-UK Media Only New data presented at ASCO 2008 from TRUST(1), the largest non-small cell lung cancer (NSCLC) Phase IV trial ever conducted, show that a broad range of NSCLC ...
Basel, Switzerland (ots/PRNewswire) - - Tolerability is an Increasingly Important Factor When Selecting Treatment Options for Patients - ABSTRACT No: 5110 (Poster 6H) Data presented at the largest oncology meeting in the world, the American Society of Clinical Oncology (ASCO), shows that the costs ...
Basel, Switzerland (ots/PRNewswire) - New data from a Phase II trial presented at the American Society of Clinical Oncology (ASCO) 2008 meeting showed that half of the patients with advanced, HER2-positive metastatic breast cancer whose disease had progressed during a Herceptin-containing regimen benefited from a ...
Basel, Switzerland (ots/PRNewswire) - - Roche Supports Patient Groups and International Health Bodies to Call for Increased Resources to Fight Viral Hepatitis - a Major Global Killer A staggering one in 12 people globally are estimated to be infected with chronic hepatitis B or C - this equates to around 500 million people worldwide.(1,2) What is even more alarming is that in some European countries up to 98% of people infected with viral hepatitis and have not ...
Basel, Switzerland (ots/PRNewswire) - Patients with breast or colorectal cancer, two of the world's most common cancers, can expect further treatment advances with Avastin(R) (bevacizumab) and Herceptin(R) (trastuzumab) following new data that is being presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago at the end of May. ...
Basel, Switzerland (ots/PRNewswire) - - Dose Adjustments Considered to be one of the Main Causes of Haemoglobin Instability in Chronic Kidney Disease Patients A new analysis has shown that once-monthly Mircera(R) maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) with significantly fewer dose changes than more ...
Basel, Switzerland (ots/PRNewswire) - - Roche Also Provides Comment on Results of "IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) (peginterferon alfa-2a) plus COPEGUS(R) (ribavirin) had a greater chance of ...
Basel, Switzerland (ots/PRNewswire) - - R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in combination with PEGASYS(R) (peginterferon alfa-2a) and ...
Basel, Switzerland (ots/PRNewswire) - - No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS(R) (peginterferon alfa-2a) treatment achieved clearance of ...
BERLIN - European Breast Cancer Conference (EBCC), April 18 (ots/PRNewswire) -- - For Non-UK and Non-US Media Only - Herceptin Offers Women With HER2-Positive Breast Cancer the Best Chance of a Cure New data presented today as part of a late breaking plenary session at EBCC in Berlin showed that Herceptin (trastuzumab) in combination with standard ...